{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73","upperLimit":"97","value":"85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Overall survival is measured from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. While OS was assessed up to 4 years, 4 year estimates were not reached. We are reporting the 24 month estimate (how many participants reached survival time of at least 24 months).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Isatuximab"}],"paramType":"NUMBER","populationDescription":"35 eligible participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From date of enrollment up to 2 years","title":"Overall Survival (24 Month Estimate)","type":"SECONDARY","unitOfMeasure":"percent of participants"}